Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin
A Phase 2a, Multi-Centre, Single Arm Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin on the Face
1 other identifier
interventional
24
1 country
2
Brief Summary
This study is primarily designed to evaluate the safety and tolerability of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face. The secondary endpoint is to determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Oct 2010
Shorter than P25 for phase_2
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 3, 2010
CompletedFirst Posted
Study publicly available on registry
October 5, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2011
CompletedJanuary 25, 2011
January 1, 2011
3 months
October 3, 2010
January 23, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To evaluate the safety of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face.
Day 43
Secondary Outcomes (1)
To determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face.
Day 43
Study Arms (1)
1
EXPERIMENTALUp to three days of treatment
Interventions
Eligibility Criteria
You may qualify if:
- Male and female patients aged 30 to 65 years.
- Female patients must be of either:
- Non-childbearing potential, provided there is a laboratory confirmed serum follicle stimulating hormone (FSH) level ≥ 40mIU/ml or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus); or
- Childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy.
- Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures, including any alteration of medications in preparation for study entry.
- Patient has agreed to allow photographs of the selected treatment area to be taken and used as part of the study data package.
You may not qualify if:
- Known sensitivity or allergy to any of the ingredients in PEP005 (ingenol mebutate) Gel.
- Current enrolment or participation in a clinical research study within 30 days of entry into this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peplinlead
Study Sites (2)
The Skin Centre
Benowa, Queensland, 4217, Australia
Specialist Connect
Woolloongabba, Queensland, 4102, Australia
Related Links
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 3, 2010
First Posted
October 5, 2010
Study Start
October 1, 2010
Primary Completion
January 1, 2011
Study Completion
January 1, 2011
Last Updated
January 25, 2011
Record last verified: 2011-01